{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:08:24Z","timestamp":1783944504646,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102583","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:04:09Z","timestamp":1779145449000},"page":"102583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-2644","authenticated-orcid":false,"given":"Emanuele","family":"Crupi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102583_bib0001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs\u2014Part B: Prostate and Urinary Tract Tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur. Urol"},{"key":"10.1016\/j.clgc.2026.102583_bib0002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral Heterogeneity of ERBB2 Amplification and HER2 Expression in Micropapillary Urothelial Carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum. Pathol"},{"key":"10.1016\/j.clgc.2026.102583_bib0003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","article-title":"Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma","volume":"4","author":"Behzato\u011flu","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.clgc.2026.102583_bib0004","first-page":"1","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","author":"Raggi","year":"2025","journal-title":"Nat. Rev. Urol"},{"key":"10.1016\/j.clgc.2026.102583_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111547","article-title":"Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer","volume":"22","author":"Wucherpfennig","year":"2021","journal-title":"Int. J. Mol. Sci"},{"key":"10.1016\/j.clgc.2026.102583_bib0006","unstructured":"Research, C. for D. E. and. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 (2024). Accessed March 28, 2026."},{"key":"10.1016\/j.clgc.2026.102583_bib0007","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.clgc.2026.102583_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.clgc.2026.102583_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res"},{"key":"10.1016\/j.clgc.2026.102583_bib0010","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/modpathol.2013.201","article-title":"Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome","volume":"27","author":"Schneider","year":"2014","journal-title":"Mod. Pathol"},{"key":"10.1016\/j.clgc.2026.102583_bib0011","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","article-title":"Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma","volume":"88","author":"Chu","year":"2025","journal-title":"Eur. Urol"},{"key":"10.1016\/j.clgc.2026.102583_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front. Oncol"},{"key":"10.1016\/j.clgc.2026.102583_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8463731","article-title":"HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder","volume":"2016","author":"Kim","year":"2016","journal-title":"Dis. Markers"},{"key":"10.1016\/j.clgc.2026.102583_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.04.012","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases","volume":"148","author":"Zheng","year":"2024","journal-title":"Hum. Pathol"},{"key":"10.1016\/j.clgc.2026.102583_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.13958","article-title":"Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma","volume":"75","author":"Weyerer","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2026.102583_bib0016","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.humpath.2018.05.005","article-title":"Small Cell Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 81 Cases","volume":"79","author":"Wang","year":"2018","journal-title":"Hum. Pathol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:18:14Z","timestamp":1783941494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000832"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102583","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102583"}}